{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:20:45Z","timestamp":1790767245753,"version":"4.1.0"},"reference-count":170,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Thanks to their anti-inflammatory, anti-oedema, and anti-allergy properties, glucocorticoids are among the most widely prescribed drugs in patients with cancer. The indications for glucocorticoid use are very wide and varied in the context of cancer and include the symptomatic management of cancer-related symptoms (compression, pain, oedema, altered general state) but also prevention or treatment of common side effects of anti-cancer therapies (nausea, allergies, etc.) or immune-related adverse events (irAE). In this review, we first give an overview of the different clinical situations where glucocorticoids are used in oncology. Next, we describe the current state of knowledge regarding the effects of these molecules on immune response, in particular anti-tumour response, and we summarize available data evaluating how these effects may interfere with the efficacy of immunotherapy using immune checkpoint inhibitors.<\/jats:p>","DOI":"10.3390\/cells11050770","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T22:35:09Z","timestamp":1645569309000},"page":"770","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era"],"prefix":"10.3390","volume":"11","author":[{"given":"Laura","family":"Kalfeist","sequence":"first","affiliation":[{"name":"Platform of Transfer in Cancer Biology, Georges-Francois Leclerc Center, 21000 Dijon, France"},{"name":"UMR INSERM 1231 \u201cLipides Nutrition Cancer\u201d, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efck","family":"Galland","sequence":"additional","affiliation":[{"name":"Platform of Transfer in Cancer Biology, Georges-Francois Leclerc Center, 21000 Dijon, France"},{"name":"UMR INSERM 1231 \u201cLipides Nutrition Cancer\u201d, 21000 Dijon, France"},{"name":"Department of Medical Oncology, Georges-Fran\u00e7ois Leclerc Center, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Ledys","sequence":"additional","affiliation":[{"name":"Platform of Transfer in Cancer Biology, Georges-Francois Leclerc Center, 21000 Dijon, France"},{"name":"UMR INSERM 1231 \u201cLipides Nutrition Cancer\u201d, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5465-8305","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[{"name":"Platform of Transfer in Cancer Biology, Georges-Francois Leclerc Center, 21000 Dijon, France"},{"name":"UMR INSERM 1231 \u201cLipides Nutrition Cancer\u201d, 21000 Dijon, France"},{"name":"Department of Medical Oncology, Georges-Fran\u00e7ois Leclerc Center, 21000 Dijon, France"},{"name":"School of Medicine, University of Burgundy Franche-Comt\u00e9, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeric","family":"Limagne","sequence":"additional","affiliation":[{"name":"Platform of Transfer in Cancer Biology, Georges-Francois Leclerc Center, 21000 Dijon, France"},{"name":"UMR INSERM 1231 \u201cLipides Nutrition Cancer\u201d, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-9194","authenticated-orcid":false,"given":"Sylvain","family":"Ladoire","sequence":"additional","affiliation":[{"name":"Platform of Transfer in Cancer Biology, Georges-Francois Leclerc Center, 21000 Dijon, France"},{"name":"UMR INSERM 1231 \u201cLipides Nutrition Cancer\u201d, 21000 Dijon, France"},{"name":"Department of Medical Oncology, Georges-Fran\u00e7ois Leclerc Center, 21000 Dijon, France"},{"name":"School of Medicine, University of Burgundy Franche-Comt\u00e9, 21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-1-4939-2895-8_14","article-title":"Glucocorticoids and Cancer","volume":"872","author":"Pufall","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23861","DOI":"10.1074\/jbc.M301843200","article-title":"Microarray Analysis Uncovers the Induction of the Proapoptotic BH3-Only Protein Bim in Multiple Models of Glucocorticoid-Induced Apoptosis","volume":"278","author":"Wang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1006\/bbrc.2000.3922","article-title":"Glucocorticoid-Induced Apoptosis in Lymphocytes","volume":"279","author":"Planey","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_4","first-page":"1681","article-title":"Mechanisms of Glucocorticoid-Mediated Apoptosis in Hematological Malignancies","volume":"8","author":"Greenstein","year":"2002","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsbmb.2007.11.003","article-title":"Dual Regulation of Glucocorticoid-Induced Leucine Zipper (GILZ) by the Glucocorticoid Receptor and the PI3-Kinase\/AKT Pathways in Multiple Myeloma","volume":"110","author":"Grugan","year":"2008","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1182\/blood-2006-11-056366","article-title":"Genomewide Identification of Prednisolone-Responsive Genes in Acute Lymphoblastic Leukemia Cells","volume":"109","author":"Tissing","year":"2007","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple Myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","article-title":"Gamma-Secretase Inhibitors Reverse Glucocorticoid Resistance in T Cell Acute Lymphoblastic Leukemia","volume":"15","author":"Real","year":"2009","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","article-title":"Gene Expression-Based Chemical Genomics Identifies Rapamycin as a Modulator of MCL1 and Glucocorticoid Resistance","volume":"10","author":"Wei","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa033513","article-title":"Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment","volume":"351","author":"Holleman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Keith, B.D. (2008). Systematic Review of the Clinical Effect of Glucocorticoids on Nonhematologic Malignancy. BMC Cancer, 8.","DOI":"10.1186\/1471-2407-8-84"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10353","DOI":"10.1074\/jbc.M213121200","article-title":"Glucocorticoid Down-Regulation of RhoA Is Required for the Steroid-Induced Organization of the Junctional Complex and Tight Junction Formation in Rat Mammary Epithelial Tumor Cells","volume":"278","author":"Rubenstein","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1158\/1535-7163.MCT-12-0621","article-title":"Contrary Regulation of Bladder Cancer Cell Proliferation and Invasion by Dexamethasone-Mediated Glucocorticoid Receptor Signals","volume":"11","author":"Zheng","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/onc.2012.138","article-title":"Glucocorticoids and Histone Deacetylase Inhibitors Cooperate to Block the Invasiveness of Basal-like Breast Cancer Cells through Novel Mechanisms","volume":"32","author":"Law","year":"2013","journal-title":"Oncogene"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1126\/science.6192498","article-title":"Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone","volume":"221","author":"Folkman","year":"1983","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24020","DOI":"10.1074\/jbc.M113.473819","article-title":"Interaction of Glucocorticoid Receptor (GR) with Estrogen Receptor (ER) \u03b1 and Activator Protein 1 (AP1) in Dexamethasone-Mediated Interference of ER\u03b1 Activity","volume":"288","author":"Karmakar","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-12-2350","article-title":"FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells","volume":"73","author":"Sahu","year":"2013","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.steroids.2016.02.019","article-title":"New Dimension of Glucocorticoids in Cancer Treatment","volume":"111","author":"Lin","year":"2016","journal-title":"Steroids"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1038\/ncomms6917","article-title":"Glucocorticoids Mediate Induction of MicroRNA-708 to Suppress Ovarian Cancer Metastasis through Targeting Rap1B","volume":"6","author":"Lin","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.bbi.2012.10.022","article-title":"The Influence of Glucocorticoid Signaling on Tumor Progression","volume":"30","author":"Volden","year":"2013","journal-title":"Brain. Behav. Immun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-019-1019-4","article-title":"Glucocorticoids Promote Breast Cancer Metastasis","volume":"567","author":"Hamelin","year":"2019","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16649","DOI":"10.1074\/jbc.M010842200","article-title":"Glucocorticoid Receptor-Mediated Protection from Apoptosis Is Associated with Induction of the Serine\/Threonine Survival Kinase Gene, Sgk-1","volume":"276","author":"Mikosz","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/0008-5472.CAN-03-2546","article-title":"Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated with Inhibition of Apoptosis in Breast Epithelial Cells","volume":"64","author":"Wu","year":"2004","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/cncr.20534","article-title":"Glucocorticoid Administration in Antiemetic Therapy: Is It Safe?","volume":"101","author":"Borces","year":"2004","journal-title":"Cancer"},{"key":"ref_25","first-page":"3112","article-title":"Glucocorticoid Cotreatment Induces Apoptosis Resistance toward Cancer Therapy in Carcinomas","volume":"63","author":"Herr","year":"2003","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10549-008-0136-9","article-title":"Glucocorticoid Receptor Expression in Breast Cancer Associates with Older Patient Age","volume":"116","author":"Belova","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.mce.2017.07.004","article-title":"Possible Roles for Glucocorticoid Signalling in Breast Cancer","volume":"466","author":"McNamara","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1178223420974667","DOI":"10.1177\/1178223420974667","article-title":"A Brief Overview of the Paradoxical Role of Glucocorticoids in Breast Cancer","volume":"14","author":"Zhidkova","year":"2020","journal-title":"Breast Cancer Basic Clin. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1200\/JCO.2013.54.3926","article-title":"Efficacy of Methylprednisolone on Pain, Fatigue, and Appetite Loss in Patients with Advanced Cancer Using Opioids: A Randomized, Placebo-Controlled, Double-Blind Trial","volume":"32","author":"Paulsen","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2012.44.4661","article-title":"Reduction of Cancer-Related Fatigue with Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients with Advanced Cancer","volume":"31","author":"Yennurajalingam","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-82028-1_1","article-title":"Guidelines for therapy of pain in cancer patients","volume":"Volume 89","author":"Zimmermann","year":"1984","journal-title":"Pain in the Cancer Patient"},{"key":"ref_32","first-page":"1126","article-title":"Bone metastases pain in the elderly","volume":"5","author":"Chouahnia","year":"2009","journal-title":"Rev. Med. Suisse"},{"key":"ref_33","first-page":"CD010756","article-title":"Corticosteroids for the Management of Cancer-Related Pain in Adults","volume":"2015","author":"Haywood","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11916-012-0273-z","article-title":"The Role of Corticosteroids in the Treatment of Pain in Cancer Patients","volume":"16","author":"Leppert","year":"2012","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1089\/jpm.2011.0260","article-title":"Dyspnea in Palliative Care: Expanding the Role of Corticosteroids","volume":"15","author":"Lin","year":"2012","journal-title":"J. Palliat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0885-3924(98)00065-7","article-title":"Dyspnea in the Advanced Cancer Patient","volume":"16","author":"Dudgeon","year":"1998","journal-title":"J. Pain Symptom Manag."},{"key":"ref_37","first-page":"CD012704","article-title":"Systemic Corticosteroids for the Management of Cancer-Related Breathlessness (Dyspnoea) in Adults","volume":"2","author":"Haywood","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpainsymman.2015.10.023","article-title":"Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial","volume":"52","author":"Hui","year":"2016","journal-title":"J. Pain Symptom Manag."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.bbi.2010.03.009","article-title":"Inflammatory Cytokines Are Associated with the Development of Symptom Burden in Patients with NSCLC Undergoing Concurrent Chemoradiation Therapy","volume":"24","author":"Wang","year":"2010","journal-title":"Brain. Behav. Immun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-009-0057-4","article-title":"The Role of Steroids in the Management of Brain Metastases: A Systematic Review and Evidence-Based Clinical Practice Guideline","volume":"96","author":"Ryken","year":"2010","journal-title":"J. Neurooncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejca.2018.08.028","article-title":"Clinical Management of Spinal Metastases-The Dutch National Guideline","volume":"104","author":"Bollen","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/nop\/npu029","article-title":"Corticosteroid Use in Neuro-Oncology: An Update","volume":"2","author":"Roth","year":"2015","journal-title":"Neuro-Oncol. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1191\/026921601673324846","article-title":"A Prospective Survey of the Use of Dexamethasone on a Palliative Care Unit","volume":"15","author":"Hardy","year":"2001","journal-title":"Palliat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11864-012-0206-4","article-title":"Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge","volume":"13","author":"Nagpal","year":"2012","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"586","DOI":"10.14423\/SMJ.0000000000000700","article-title":"Management of Metastatic Spinal Cord Compression","volume":"110","author":"Sodji","year":"2017","journal-title":"South. Med. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF01402610","article-title":"Metastatic Spinal Cord Compression. Occurrence, Symptoms, Clinical Presentations and Prognosis in 398 Patients with Spinal Cord Compression","volume":"107","author":"Bach","year":"1990","journal-title":"Acta Neurochir."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpainsymman.2013.08.022","article-title":"Recommendations for Bowel Obstruction with Peritoneal Carcinomatosis","volume":"48","author":"Laval","year":"2014","journal-title":"J. Pain Symptom Manag."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1038\/sj.bjc.6601090","article-title":"Standards, Options and Recommendations for the Use of Appetite Stimulants in Oncology (2000)","volume":"89","author":"Desport","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1089\/jpm.2013.0324","article-title":"Use of Corticosteroids for Anorexia in Palliative Medicine: A Systematic Review","volume":"17","author":"Miller","year":"2014","journal-title":"J. Palliat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/SPC.0000000000000093","article-title":"Role of Corticosteroids for Fatigue in Advanced Incurable Cancer: Is It a \u201cwonder Drug\u201d or \u201cDeal with the Devil\u201d","volume":"8","author":"Yennurajalingam","year":"2014","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_51","first-page":"1041","article-title":"The Use and Toxicity of Steroids in the Management of Patients with Brain Metastases","volume":"16","author":"Sturdza","year":"2008","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/annonc\/mdl347","article-title":"Antiemetic Activity of Corticosteroids in Patients Receiving Cancer Chemotherapy: Dosing, Efficacy, and Tolerability Analysis","volume":"18","author":"Grunberg","year":"2007","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1515\/jtim-2016-0010","article-title":"Corticosteroids, the Oldest Agent in the Prevention of Chemotherapy-Induced Nausea and Vomiting: What about the Guidelines?","volume":"4","year":"2016","journal-title":"J. Transl. Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/cs0940557","article-title":"Anti-Inflammatory Actions of Glucocorticoids: Molecular Mechanisms","volume":"94","author":"Barnes","year":"1998","journal-title":"Clin. Sci."},{"key":"ref_56","first-page":"531","article-title":"Dexamethasone Reduces Pain, Vomiting and Overall Complications Following Tonsillectomy in Adults: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"36","author":"Diakos","year":"2011","journal-title":"Clin. Otolaryngol. Off. J. ENT-UK Off. J. Neth. Soc. Oto-Rhino-Laryngol. Cervico-Facial Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2013.10.008","article-title":"The Cellular Mechanisms of the Antiemetic Action of Dexamethasone and Related Glucocorticoids against Vomiting","volume":"722","author":"Chu","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_58","first-page":"55","article-title":"How Do Glucocorticoids Influence Stress Responses? Integrating Permissive, Suppressive, Stimulatory, and Preparative Actions","volume":"21","author":"Sapolsky","year":"2000","journal-title":"Endocr. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1385\/MO:18:2:131","article-title":"Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy in Patients with Acute Emesis: A Pilot Study with ACTH-Depot plus Tropisetron","volume":"18","author":"Santini","year":"2001","journal-title":"Med. Oncol."},{"key":"ref_60","first-page":"1051","article-title":"Cisplatin Induces Serotonin Release from Human Peripheral Blood Mononuclear Cells of Cancer Patients and Methylprednisolone Inhibits This Effect","volume":"4","author":"Mantovani","year":"1997","journal-title":"Oncol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/01902148.2014.979516","article-title":"The Pathogenesis of Bleomycin-Induced Lung Injury in Animals and Its Applicability to Human Idiopathic Pulmonary Fibrosis","volume":"41","author":"Williamson","year":"2015","journal-title":"Exp. Lung Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.lungcan.2011.10.008","article-title":"Fatal Interstitial Lung Disease Associated with High Erlotinib and Metabolite Levels. A Case Report and a Review of the Literature","volume":"75","author":"Lankheet","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_63","first-page":"PO.17.00026","article-title":"Drug-Related Pneumonitis in the Era of Precision Cancer Therapy","volume":"1","author":"Nishino","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1378\/chest.07-0851","article-title":"Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors","volume":"133","author":"Vahid","year":"2008","journal-title":"Chest"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S1470-2045(15)00199-0","article-title":"Dexamethasone in the Prophylaxis of Radiation-Induced Pain Flare after Palliative Radiotherapy for Bone Metastases: A Double-Blind, Randomised Placebo-Controlled, Phase 3 Trial","volume":"16","author":"Chow","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"196","DOI":"10.23822\/EurAnnACI.1764-1489.15","article-title":"Corticosteroids in Management of Anaphylaxis; a Systematic Review of Evidence","volume":"49","author":"Liyanage","year":"2017","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"ref_68","first-page":"iv100","article-title":"Management of Infusion Reactions to Systemic Anticancer Therapy: ESMO Clinical Practice Guidelines","volume":"28","author":"Blasco","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/187152810792231887","article-title":"Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview","volume":"9","author":"Syrigou","year":"2010","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/00002018-200124100-00005","article-title":"Prevention and Management of Antineoplastic-Induced Hypersensitivity Reactions","volume":"24","author":"Zanotti","year":"2001","journal-title":"Drug Saf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/oxfordjournals.annonc.a010806","article-title":"Rapid Intravenous Premedication with Dexamethasone Prevents Hypersensitivity Reactions to Paclitaxel","volume":"7","author":"Gennari","year":"1996","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0269216320986717","article-title":"Practice Review: Evidence-Based Quality Use of Corticosteroids in the Palliative Care of Patients with Advanced Cancer","volume":"35","author":"Hardy","year":"2021","journal-title":"Palliat. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ecl.2005.01.002","article-title":"Adrenal Corticosteroid Biosynthesis, Metabolism, and Action","volume":"34","author":"Arlt","year":"2005","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.270.5234.286","article-title":"Immunosuppression by Glucocorticoids: Inhibition of NF-Kappa B Activity through Induction of I Kappa B Synthesis","volume":"270","author":"Auphan","year":"1995","journal-title":"Science"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory Action of Glucocorticoids--New Mechanisms for Old Drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0092-8674(90)90395-U","article-title":"Antitumor Promotion and Antiinflammation: Down-Modulation of AP-1 (Fos\/Jun) Activity by Glucocorticoid Hormone","volume":"62","author":"Jonat","year":"1990","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2013.09.007","article-title":"The Biology of the Glucocorticoid Receptor: New Signaling Mechanisms in Health and Disease","volume":"132","author":"Oakley","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1084\/jem.20011629","article-title":"In Vitro Generation of Interleukin 10-Producing Regulatory CD4(+) T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)- and Th2-Inducing Cytokines","volume":"195","author":"Barrat","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.tips.2018.11.002","article-title":"Non-Genomic Effects of Glucocorticoids: An Updated View","volume":"40","author":"Panettieri","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.1038\/ncomms7062","article-title":"Glucocorticoids Suppress Inflammation via the Upregulation of Negative Regulator IRAK-M","volume":"6","author":"Miyata","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nrrheum.2011.59","article-title":"Role of GILZ in Immune Regulation, Glucocorticoid Actions and Rheumatoid Arthritis","volume":"7","author":"Beaulieu","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","article-title":"Cytokine Modulation by Glucocorticoids: Mechanisms and Actions in Cellular Studies","volume":"10","author":"Brattsand","year":"1996","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01966828","article-title":"Influence of Glucocorticoids on Histamine Release and 45calcium Uptake by Isolated Rat Mast Cells","volume":"14","author":"Grosman","year":"1984","journal-title":"Agents Actions"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1081-1206(10)63238-3","article-title":"Glucocorticosteroids Inhibit Leukotriene Production","volume":"78","author":"Crocker","year":"1997","journal-title":"Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1210\/endo-119-1-62","article-title":"Inhibition of Prostaglandin Synthesis by Glucocorticoids in Human Endothelial Cells","volume":"119","author":"Lewis","year":"1986","journal-title":"Endocrinology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.89.21.9991","article-title":"A Mechanism for the Antiinflammatory Effects of Corticosteroids: The Glucocorticoid Receptor Regulates Leukocyte Adhesion to Endothelial Cells and Expression of Endothelial-Leukocyte Adhesion Molecule 1 and Intercellular Adhesion Molecule 1","volume":"89","author":"Cronstein","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Goulding, N.J., and Flower, R.J. (2001). Glucocorticoids and Leukocyte Adhesion. Glucocorticoids, Birkh\u00e4user.","DOI":"10.1007\/978-3-0348-8348-1"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3389\/fimmu.2019.02028","article-title":"More Than Suppression: Glucocorticoid Action on Monocytes and Macrophages","volume":"10","author":"Ehrchen","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage Plasticity, Polarization, and Function in Health and Disease","volume":"233","author":"Mohammadian","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_91","first-page":"105","article-title":"Glucocorticoids Inhibit Dendritic Cell Maturation Induced by Toll-like Receptor 7 and Toll-like Receptor 8","volume":"91","author":"Antonios","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000236268","article-title":"Modulation of MHC Gene Expression by Glucocorticoid Hormones","volume":"99","author":"Scudeletti","year":"1992","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune Regulation by Glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI200418975","article-title":"Enhancement of MEK\/ERK Signaling Promotes Glucocorticoid Resistance in CD4+ T Cells","volume":"113","author":"Tsitoura","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4049\/jimmunol.123.4.1624","article-title":"Glucocorticoid-Induced Inhibition of T Cell Growth Factor Production: I. The Effect on Mitogen-Induced Lymphocyte Proliferation","volume":"123","author":"Gillis","year":"1979","journal-title":"J. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1196\/annals.1321.010","article-title":"Glucocorticoids and the Th1\/Th2 Balance","volume":"1024","author":"Elenkov","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fendo.2018.00235","article-title":"Regulatory and Mechanistic Actions of Glucocorticoids on T and Inflammatory Cells","volume":"9","author":"Liberman","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jaci.2004.07.014","article-title":"Glucocorticoids Upregulate FOXP3 Expression and Regulatory T Cells in Asthma","volume":"114","author":"Karagiannidis","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2015.05.010","article-title":"GILZ Regulates Th17 Responses and Restrains IL-17-Mediated Skin Inflammation","volume":"61","author":"Jones","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature11981","article-title":"Dynamic Regulatory Network Controlling TH17 Cell Differentiation","volume":"496","author":"Yosef","year":"2013","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The Immunobiology of Cancer Immunosurveillance and Immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"ref_102","first-page":"696","article-title":"Corticosteroid Use in Rheumatoid Arthritis: Prevalence, Predictors, Correlates, and Outcomes","volume":"34","author":"Caplan","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of Long-Term Oral Corticosteroid Therapy and Its Side-Effects in Severe Asthma in Adults: A Focused Review of the Impact Data in the Literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"23002","DOI":"10.1038\/srep23002","article-title":"Effects of Systemically Administered Hydrocortisone on the Human Immunome","volume":"6","author":"Olnes","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/neuonc\/noq001","article-title":"Systemic Immune Suppression in Glioblastoma: The Interplay between CD14+HLA-DRlo\/Neg Monocytes, Tumor Factors, and Dexamethasone","volume":"12","author":"Gustafson","year":"2010","journal-title":"Neuro-Oncology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e1358839","DOI":"10.1080\/2162402X.2017.1358839","article-title":"In-Depth Immunophenotyping of Patients with Glioblastoma Multiforme: Impact of Steroid Treatment","volume":"6","author":"Chitadze","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e1641390","DOI":"10.1080\/2162402X.2019.1641390","article-title":"Dexamethasone Differentially Depletes Tumour and Peripheral Blood Lymphocytes and Can Impact the Efficacy of Chemotherapy\/Checkpoint Blockade Combination Treatment","volume":"8","author":"Aston","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2018.1500108","article-title":"Contrasting Impact of Corticosteroids on Anti-PD-1 Immunotherapy Efficacy for Tumor Histologies Located within or Outside the Central Nervous System","volume":"7","author":"Maxwell","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-Induced Immunosuppression: Mechanisms and Implications for Immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Xing, K., Gu, B., Zhang, P., and Wu, X. (2015). Dexamethasone Enhances Programmed Cell Death 1 (PD-1) Expression during T Cell Activation: An Insight into the Optimum Application of Glucocorticoids in Anti-Cancer Therapy. BMC Immunol., 16.","DOI":"10.1186\/s12865-015-0103-2"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","article-title":"Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment","volume":"53","author":"Acharya","year":"2020","journal-title":"Immunity"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Yizhak","year":"2018","journal-title":"Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen Vaccine Generates Intratumoral T Cell Responses in Phase Ib Glioblastoma Trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus Axitinib versus Sunitinib Monotherapy as First-Line Treatment of Advanced Renal Cell Carcinoma (KEYNOTE-426): Extended Follow-up from a Randomised, Open-Label, Phase 3 Trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol."},{"key":"ref_118","first-page":"1798","article-title":"Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes","volume":"22","author":"Kim","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1158\/2326-6066.CIR-14-0217","article-title":"Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-Term Ipilimumab Survivors at a Single Referral Center","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Voskens, C.J., Goldinger, S.M., Loquai, C., Robert, C., Kaehler, K.C., Berking, C., Bergmann, T., Bockmeyer, C.L., Eigentler, T., and Fluck, M. (2013). The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053745"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative Safety of Immune Checkpoint Inhibitors in Cancer: Systematic Review and Network Meta-Analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-Mediated Thyroid Dysfunction during T-Cell Checkpoint Blockade in Patients with Non-Small-Cell Lung Cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e1231292","DOI":"10.1080\/2162402X.2016.1231292","article-title":"Characterization of Nivolumab-Associated Skin Reactions in Patients with Metastatic Non-Small Cell Lung Cancer","volume":"5","author":"Diem","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-Related Adverse Events Associated with Anti-PD-1\/PD-L1 Treatment for Malignancies: A Meta-Analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_127","first-page":"61","article-title":"Gene Profiling Reveals Unknown Enhancing and Suppressive Actions of Glucocorticoids on Immune Cells","volume":"16","author":"Galon","year":"2002","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","article-title":"Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System","volume":"10","author":"Strehl","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing Toxicities Associated with Immune Checkpoint Inhibitors: Consensus Recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-Related Adverse Events with Immune Checkpoint Blockade: A Comprehensive Review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of Onset and Resolution of Immune-Related Adverse Events of Special Interest with Ipilimumab: Detailed Safety Analysis from a Phase 3 Trial in Patients with Advanced Melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"ref_135","first-page":"1759","article-title":"Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events","volume":"16","author":"Luo","year":"2021","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early Introduction of Selective Immunosuppressive Therapy Associated with Favorable Clinical Outcomes in Patients with Immune Checkpoint Inhibitor-Induced Colitis","volume":"7","author":"Ali","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_138","first-page":"1771","article-title":"Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1684\/ejd.2014.2471","article-title":"Single-Center Study under a French Temporary Authorization for Use (TAU) Protocol for Ipilimumab in Metastatic Melanoma: Negative Impact of Baseline Corticosteroids","volume":"25","author":"Chasset","year":"2015","journal-title":"Eur. J. Dermatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2017.10.009","article-title":"Concomitant Use of Corticosteroids and Immune Checkpoint Inhibitors in Patients with Hematologic or Solid Neoplasms: A Systematic Review","volume":"120","author":"Garant","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2019.37.7_suppl.542","article-title":"Safety and Efficacy of Nivolumab in Metastatic Renal Cell Carcinoma (MRCC): Final Analysis from the NIVOREN GETUG AFU 26 Study","volume":"37","author":"Albiges","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"v391","DOI":"10.1093\/annonc\/mdz249.062","article-title":"Impact of Corticosteroids on Nivolumab Activity in Metastatic Clear Cell Renal Cell Carcinoma","volume":"30","author":"Lefort","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejca.2020.09.032","article-title":"How to Manage Patients with Corticosteroids in Oncology in the Era of Immunotherapy?","volume":"141","author":"Aldea","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e000457","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of Peripheral Blood Immune Cells by Early Use of Steroids and Its Association with Clinical Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors","volume":"4","author":"Galli","year":"2019","journal-title":"ESMO Open"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Petrelli, F., Signorelli, D., Ghidini, M., Ghidini, A., Pizzutilo, E.G., Ruggieri, L., Cabiddu, M., Borgonovo, K., Dognini, G., and Brighenti, M. (2020). Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers, 12.","DOI":"10.3390\/cancers12030546"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab","volume":"23","author":"Toi","year":"2018","journal-title":"Oncologist"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity Correlates with Tumor Regression in Patients with Metastatic Melanoma Treated with Anti-Cytotoxic T-Lymphocyte Antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-World Efficacy and Safety of Nivolumab in Previously-Treated Metastatic Renal Cell Carcinoma, and Association between Immune-Related Adverse Events and Survival: The Italian Expanded Access Program","volume":"7","author":"Verzoni","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_153","first-page":"338","article-title":"Exceptional Response of Brain Metastases to Short Course Nivolumab While on High-Dose Steroids","volume":"77","author":"Mulders","year":"2019","journal-title":"Neth. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-Dose Glucocorticoids for the Treatment of Ipilimumab-Induced Hypophysitis Is Associated with Reduced Survival in Patients with Melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3389\/fimmu.2019.01654","article-title":"Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer","volume":"10","author":"Opzoomer","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-17-0895","article-title":"Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, Which Associate with Survival in Metastatic Colorectal Cancer","volume":"23","author":"Scurr","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune Induction Strategies in Metastatic Triple-Negative Breast Cancer to Enhance the Sensitivity to PD-1 Blockade: The TONIC Trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer Cell-Autonomous Contribution of Type I Interferon Signaling to the Efficacy of Chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic Death of Colon Cancer Cells Treated with Oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"ref_163","first-page":"1657","article-title":"A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407","volume":"15","author":"Vicente","year":"2020","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary Results from IMpassion131, a Double-Blind, Placebo-Controlled, Randomised Phase III Trial of First-Line Paclitaxel with or without Atezolizumab for Unresectable Locally Advanced\/Metastatic Triple-Negative Breast Cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"JCO2101200","DOI":"10.1200\/JCO.21.01200","article-title":"Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions","volume":"39","author":"Lansinger","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","volume":"379","author":"Luft","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/5\/770\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:25:19Z","timestamp":1760135119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/5\/770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":170,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cells11050770"],"URL":"https:\/\/doi.org\/10.3390\/cells11050770","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]}}}